EP2180884A4 - Administration par voie centrale de formulations stables d'agents thérapeutiques pour traiter des affections du snc - Google Patents

Administration par voie centrale de formulations stables d'agents thérapeutiques pour traiter des affections du snc

Info

Publication number
EP2180884A4
EP2180884A4 EP08794800.6A EP08794800A EP2180884A4 EP 2180884 A4 EP2180884 A4 EP 2180884A4 EP 08794800 A EP08794800 A EP 08794800A EP 2180884 A4 EP2180884 A4 EP 2180884A4
Authority
EP
European Patent Office
Prior art keywords
therapeutic agents
stable formulations
central administration
cns conditions
cns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08794800.6A
Other languages
German (de)
English (en)
Other versions
EP2180884A1 (fr
Inventor
Karen E Stevens
Daniel J Abrams
Tom Anchordoquy
Raymond Bunch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado
Original Assignee
University of Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado filed Critical University of Colorado
Publication of EP2180884A1 publication Critical patent/EP2180884A1/fr
Publication of EP2180884A4 publication Critical patent/EP2180884A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP08794800.6A 2007-07-25 2008-07-25 Administration par voie centrale de formulations stables d'agents thérapeutiques pour traiter des affections du snc Withdrawn EP2180884A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96655407P 2007-07-25 2007-07-25
PCT/US2008/009109 WO2009014762A1 (fr) 2007-07-25 2008-07-25 Administration par voie centrale de formulations stables d'agents thérapeutiques pour traiter des affections du snc

Publications (2)

Publication Number Publication Date
EP2180884A1 EP2180884A1 (fr) 2010-05-05
EP2180884A4 true EP2180884A4 (fr) 2013-04-17

Family

ID=40281688

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08794800.6A Withdrawn EP2180884A4 (fr) 2007-07-25 2008-07-25 Administration par voie centrale de formulations stables d'agents thérapeutiques pour traiter des affections du snc

Country Status (4)

Country Link
EP (1) EP2180884A4 (fr)
AU (1) AU2008279636A1 (fr)
CA (1) CA2694122A1 (fr)
WO (1) WO2009014762A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008095221A1 (fr) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Traitement du syndrome hypercinétique
CA2720254A1 (fr) * 2008-04-01 2009-12-17 Regents Of The University Of Colorado, A Body Corporate Procedes et compositions pour l'administration intracerebroventriculaire de felbamate
US20110207718A1 (en) * 2008-08-06 2011-08-25 Gosforth Centre (Holdings) Pty Ltd. Compositions and methods for treating psychiatric disorders
EP3490653A1 (fr) 2016-07-28 2019-06-05 Cerebral Therapeutics Échantillonneur intra-ventriculaire implantable et dispositif d'accès de perfusion.
CA3073219A1 (fr) 2017-10-23 2019-05-02 Cerebral Therapeutics LLC Solutions d'acide valproique a haute concentration pour le traitement de troubles neurologiques
EP3520803A1 (fr) * 2018-01-31 2019-08-07 Zarodex Therapeutics Limited Nouvelles utilisations
TW202114655A (zh) 2019-08-14 2021-04-16 瑞士商辛鐵堤卡公司 左乙拉西坦(levetiracetam)之鞘內投藥
US12102636B2 (en) * 2021-02-11 2024-10-01 Medtronic, Inc. Administration of antipsychotics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0400609A1 (fr) * 1989-06-02 1990-12-05 Ciba-Geigy Ag Solutions intraveineuses à déclenchement d'action rapide
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
WO2007084541A2 (fr) * 2006-01-17 2007-07-26 Regents Of The University Of Colorado Administration centrale de formulations stables d'agents thérapeutiques dans le traitement d'affections du système nerveux central (snc)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2716680B1 (fr) * 1994-02-25 1996-04-05 Adir Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US7528108B2 (en) * 2005-04-26 2009-05-05 Ambryx Biotechnology, Inc. Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0400609A1 (fr) * 1989-06-02 1990-12-05 Ciba-Geigy Ag Solutions intraveineuses à déclenchement d'action rapide
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
WO2007084541A2 (fr) * 2006-01-17 2007-07-26 Regents Of The University Of Colorado Administration centrale de formulations stables d'agents thérapeutiques dans le traitement d'affections du système nerveux central (snc)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JANG J ET AL: "USE OF 2 HYDROXYPROPYL-BETA-CYCLODEXTRIN AS AN INTRATHECAL DRUG VEHICLE WITHOPIOIDS", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 261, no. 2, 1 January 1992 (1992-01-01), pages 592 - 600, XP008085290, ISSN: 0022-3565 *
See also references of WO2009014762A1 *
YAKSH T L ET AL: "The utility of 2-hydroxypropyl-beta-cyclodextrin as a vehicle for the intracerebral and intrathecal administration of drugs", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 48, no. 7, 1 January 1991 (1991-01-01), pages 623 - 633, XP025549532, ISSN: 0024-3205, [retrieved on 19910101], DOI: 10.1016/0024-3205(91)90537-L *

Also Published As

Publication number Publication date
EP2180884A1 (fr) 2010-05-05
CA2694122A1 (fr) 2009-01-29
WO2009014762A1 (fr) 2009-01-29
AU2008279636A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
IL273683A (en) Drug cores for sustained release of therapeutic agents
IL192841A0 (en) Central administration of stable formulations of therapeutic agents for cns conditions
HK1143731A1 (zh) 利培酮類化合物的緩釋製劑
ZA200900345B (en) Preparation of pharmaceutical formulations
EP2180884A4 (fr) Administration par voie centrale de formulations stables d&#39;agents thérapeutiques pour traiter des affections du snc
EP2419138A4 (fr) Compositions de gel pour l&#39;administration de composes pharmaceutiquement actifs
ZA201101523B (en) Linaclotide-containing formulations for oral administration
EP2174667A4 (fr) Agent pour le traitement de l&#39;ophtalmie contenant un inhibiteur du récepteur de l&#39;interleukine 6 en tant qu&#39;ingrédient actif
IL211293A (en) Combination factors for the preparation of a drug for the treatment of tuberculosis
EP2449114A4 (fr) Formulations lipidiques inédites permettant l&#39;administration d&#39;agents thérapeutiques en direction de tumeurs solides
EP2207802A4 (fr) Administration intranasale d&#39;agents actifs sur le système nerveux central
IL201581A (en) Pharmaceutical formulations containing fatty acid derivatives and ion-forming substances
IL180031A0 (en) Stable pharmaceutical formulations of benzimidazole compounds
IL202083A0 (en) Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
HK1142823A1 (en) Formulations for the oral administration of therapeutic agents and related methods
EP2217216A4 (fr) Préparation à biodisponibilité accrue pour administration orale d&#39;agents polaires
EP2124552A4 (fr) Formulations pharmaceutiques à libération prolongée de s-adénosylméthionine
IL201465A0 (en) Self-precipitating pharmaceutical formulations for the modified release of active principle
EP2185112A4 (fr) Compositions et formulations thérapeutiques stabilisées
IL201418A0 (en) Therapeutic agent for glaucoma containing adenosine derivative as active ingredient
EP2583972A4 (fr) Agent thérapeutique pour des maladies inflammatoires contenant de l&#39;adénosine n1-oxyde en tant que principe actif
ZA200907834B (en) Methods of treatment using intravenoujs formulations comprising temozolomide
ZA201100944B (en) Oral formulations of chemotherapeutic agents
IL205644A0 (en) Methods for administering corticosteroid formulations
EP1948199A4 (fr) Compositions pharmaceutiques pour l&#39;administration d&#39;aptameres

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130320

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/10 20060101ALI20130314BHEP

Ipc: A61K 47/40 20060101ALI20130314BHEP

Ipc: A61K 9/22 20060101AFI20130314BHEP

17Q First examination report despatched

Effective date: 20140507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170823